Hims Halts Sale of Compounded Wegovy After FDA Investigation Threat

Hims & Hers (HIMS) has canceled plans to sell a compounded version of Novo Nordisk’s (NVO) GLP-1 weight-loss pill following FDA warnings and a potential DOJ investigation. In a Saturday X post, the company stated it stopped offering access after “constructive conversations” with industry stakeholders. The move ends a recent plan to launch an oral compounded form of Wegovy, following legal threats from Novo and rapid regulatory pressure. The FDA had earlier warned of restricting active ingredients used in similar alternatives to approved medications, and HIMS was referred to the Department of Justice. The decision follows a recent approval of Wegovy in pill form, which has driven early strong prescriptions for Novo despite competition from compounded generics and pricing pressure.